Brit Mollenhauer, MD, received her medical degree from the University Medical Center in Goettingen, Germany, in 2000 and stayed there for her residency training in neurology until 2005. From 2005 to 2007, Dr. Mollenhauer visited Harvard Medical School in Boston, Massachusetts, as a postdoctoral fellow. At Harvard, she worked on developing biomarkers—objective measures of disease—and studied alpha-synuclein, a sticky protein that clumps in the brains of people with Parkinson's disease (PD), in cerebrospinal fluid. Since June 2007, she has been an assistant professor of neurology at Georg-August-University Goettingen and Movement Disorder Paracelsus-Elena-Klinik, Kassel.

Given Dr. Mollenhauer's background in neurochemistry, her research team focuses on the detection of biomarkers in human bodily fluids and the development of experimental techniques for improved diagnosis of movement disorders. At Movement Disorder Paracelsus-Elena-Klinik, Kassel, she conducts clinical research involving volunteers with REM sleep behavior disorder (RBD) and newly diagnosed Parkinson's. Dr. Mollenhauer has published more than 125 scientific articles. She is a member of the executive steering committee and co-chair of the Bioanalytics Core of the Parkinson Progression Marker Initiative (PPMI), The Michael J. Fox Foundation's landmark clinical study to find biomarkers—disease indicators that are critical missing links in the search for better Parkinson's treatments.